{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:23:59Z","timestamp":1787660639258,"version":"build-2736575974"},"reference-count":19,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Oncol.","Current Oncology"],"abstract":"<jats:p>We report early toxicity outcomes after institutional implementation of prostate SBRT using 42.7 Gy in seven fractions delivered with either MR-guided adaptive SBRT (MRgSBRT) or CT-guided non-adaptive SBRT (CTgSBRT). Between July 2019 and May 2023, 216 patients received this regimen. Genitourinary (GU) and gastrointestinal (GI) toxicities were retrospectively assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Most patients had intermediate-risk disease (86%), and 14% had high-risk disease. Median prostate volume was 40 mL, and median baseline International Prostate Symptom Score (IPSS) was 8 among patients with available data. MRgSBRT and CTgSBRT were used in 100 (46%) and 116 (54%) patients, respectively. At a median follow-up of 19 months, 12- and 24-month grade \u2265 2 GU toxicity rates were 20.0% and 18.2%, while grade \u2265 2 GI toxicity rates were 3.5% and 3.6%, respectively. No statistically significant platform-related differences were detected; however, these comparisons were exploratory and potentially confounded by nonrandomized platform selection, treatment era, rectal-spacer use, adaptive workflow and differing PTV margins. On univariable analysis, baseline GU symptoms were associated with higher 12-month grade \u2265 2 GU toxicity (OR, 3.68; 95% CI, 1.52\u201310.37; p = 0.007), while prostate-volume category was not significantly associated with this endpoint.<\/jats:p>","DOI":"10.3390\/curroncol33090504","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T11:27:19Z","timestamp":1787657239000},"page":"504","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Initial Experience with MR-Guided or CT-Guided Stereotactic Body Radiotherapy for Prostate Cancer"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1559-6447","authenticated-orcid":false,"given":"Marc Vincent N.","family":"Barcelona","sequence":"first","affiliation":[{"name":"Radiation Medicine Program, Princess Margaret Cancer Centre, University of Toronto, 610 University Ave, Toronto, ON M5G 2M9, Canada"},{"name":"Department of Radiotherapy, Jose R. Reyes Memorial Medical Center, San Lazaro Compound, Rizal Ave. Sta Cruz, Manila 1003, Philippines"},{"name":"Department of Radiation Oncology, Manila Doctors Hospital, 667 United Nations Avenue, Ermita, Manila 1000, Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8110-3145","authenticated-orcid":false,"given":"Noelia","family":"Sanmamed Salgado","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, San Carlos Hospital, Calle del Prof Mart\u00edn Lagos, s\/n, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique Gutierrez","family":"Valencia","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Dr. H. Bliss Murphy Cancer Centre, Memorial University of Newfoundland, 300 Prince Philip Drive, St. John\u2019s, NL A1B 3V6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Berlin","sequence":"additional","affiliation":[{"name":"Radiation Medicine Program, Princess Margaret Cancer Centre, University of Toronto, 610 University Ave, Toronto, ON M5G 2M9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0555-8754","authenticated-orcid":false,"given":"Rachel","family":"Glicksman","sequence":"additional","affiliation":[{"name":"Radiation Medicine Program, Princess Margaret Cancer Centre, University of Toronto, 610 University Ave, Toronto, ON M5G 2M9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Catton","sequence":"additional","affiliation":[{"name":"Radiation Medicine Program, Princess Margaret Cancer Centre, University of Toronto, 610 University Ave, Toronto, ON M5G 2M9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"McPartlin","sequence":"additional","affiliation":[{"name":"Radiation Medicine Program, Princess Margaret Cancer Centre, University of Toronto, 610 University Ave, Toronto, ON M5G 2M9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0873-0254","authenticated-orcid":false,"given":"Jeff D.","family":"Winter","sequence":"additional","affiliation":[{"name":"Radiation Medicine Program, Princess Margaret Cancer Centre, University of Toronto, 610 University Ave, Toronto, ON M5G 2M9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Dang","sequence":"additional","affiliation":[{"name":"Radiation Medicine Program, Princess Margaret Cancer Centre, University of Toronto, 610 University Ave, Toronto, ON M5G 2M9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0468-6241","authenticated-orcid":false,"given":"Vickie","family":"Kong","sequence":"additional","affiliation":[{"name":"Radiation Medicine Program, Princess Margaret Cancer Centre, University of Toronto, 610 University Ave, Toronto, ON M5G 2M9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangqing","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University Health Network, 610 University Ave, Toronto, ON M5G 2M9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3815-7703","authenticated-orcid":false,"given":"Peter","family":"Chung","sequence":"additional","affiliation":[{"name":"Radiation Medicine Program, Princess Margaret Cancer Centre, University of Toronto, 610 University Ave, Toronto, ON M5G 2M9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on Prostate Cancer: Planning for the Surge in Cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-Hypofractionated versus Conventionally Fractionated Radiotherapy for Prostate Cancer: 5-Year Outcomes of the HYPO-RT-PC Randomised, Non-Inferiority, Phase 3 Trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer","volume":"391","author":"Griffin","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-Modulated Radiotherapy versus Stereotactic Body Radiotherapy for Prostate Cancer (PACE-B): 2-Year Toxicity Results from an Open-Label, Randomised, Phase 3, Non-Inferiority Trial","volume":"23","author":"Tree","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","article-title":"Prostate Cancer, Version 3.2024","volume":"22","author":"Schaeffer","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S1470-2045(25)00205-0","article-title":"Intensity-Modulated Moderately Hypofractionated Radiotherapy versus Stereotactic Body Radiotherapy for Prostate Cancer (PACE-C): Early Toxicity Results from a Randomised, Open-Label, Phase 3, Non-Inferiority Trial","volume":"26","author":"Tree","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.eururo.2024.10.026","article-title":"Magnetic Resonance Imaging Versus Computed Tomography Guidance for Stereotactic Body Radiotherapy in Prostate Cancer: 2-Year Outcomes from the MIRAGE Randomized Clinical Trial","volume":"87","author":"Kishan","year":"2025","journal-title":"Eur. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e2410819","DOI":"10.1001\/jamanetworkopen.2024.10819","article-title":"Safety and Tolerability of Online Adaptive High-Field Magnetic Resonance-Guided Radiotherapy","volume":"7","author":"Westerhoff","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S1507","DOI":"10.1016\/S0167-8140(22)03672-6","article-title":"PO-1708 Application of Dose Accumulation for PTV Margin Design in MR-Guided Adaptive Prostate SBRT","volume":"170","author":"Winter","year":"2022","journal-title":"Radiother. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1007\/s11547-023-01624-7","article-title":"Linac-Based versus MR-Guided SBRT for Localized Prostate Cancer: A Comparative Evaluation of Acute Tolerability","volume":"128","author":"Nicosia","year":"2023","journal-title":"Radiol. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S1470-2045(25)00656-4","article-title":"Ultra-Hypofractionated versus Conventionally Fractionated Radiotherapy for Localised Prostate Cancer (HYPO-RT-PC): 10-Year Outcomes of an Open-Label, Randomised, Phase 3, Non-Inferiority Trial","volume":"27","author":"Nilsson","year":"2026","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Ng, J., Gregucci, F., Pennell, R.T., Nagar, H., Golden, E.B., Knisely, J.P.S., Sanfilippo, N.J., and Formenti, S.C. (2023). MRI-LINAC: A Transformative Technology in Radiation Oncology. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1117874"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Ocanto, A., Torres, L., Montijano, M., Rinc\u00f3n, D., Fern\u00e1ndez, C., Sevilla, B., Gonsalves, D., Teja, M., Guijarro, M., and Glar\u00eda, L. (2024). MR-LINAC, a New Partner in Radiation Oncology: Current Landscape. Cancers, 16.","DOI":"10.3390\/cancers16020270"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"20210800","DOI":"10.1259\/bjr.20210800","article-title":"MR-Guided Radiotherapy for Prostate Cancer: State of the Art and Future Perspectives","volume":"95","author":"Sritharan","year":"2022","journal-title":"Br. J. Radiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13014-020-01510-w","article-title":"1.5 T MR-Guided and Daily Adapted SBRT for Prostate Cancer: Feasibility, Preliminary Clinical Tolerability, Quality of Life and Patient-Reported Outcomes during Treatment","volume":"15","author":"Alongi","year":"2020","journal-title":"Radiat. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1002\/cncr.34836","article-title":"Acute Toxicity Comparison of Magnetic Resonance-guided Adaptive versus Fiducial or Computed Tomography-guided Non-Adaptive Prostate Stereotactic Body Radiotherapy: A Systematic Review and Meta-analysis","volume":"129","author":"Leeman","year":"2023","journal-title":"Cancer"},{"key":"ref_17","unstructured":"National Cancer Institute (2017). Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ijrobp.2020.09.054","article-title":"Prostate Stereotactic Body Radiation Therapy: An Overview of Toxicity and Dose Response","volume":"110","author":"Wang","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.ijrobp.2025.05.008","article-title":"HERMES: Randomized Trial of 2-Fraction or 5-Fraction Magnetic Resonance Imaging-Guided Adaptive Prostate Radiation Therapy","volume":"123","author":"Cooper","year":"2025","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/9\/504\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T11:42:32Z","timestamp":1787658152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/9\/504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":19,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["curroncol33090504"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33090504","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]}}}